Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease

Wang, Yumin; Wu, Shuang; Li, Qiang; Lang, Weihong; Li, Wenjing; Jiang, Xiaodong; Wan, Zhirong; Chen, Jichao; Wang, Hongquan

doi:10.3389/fphar.2022.977521

Cited by 23 publications

(18 citation statements)

References 117 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(-)-Epigallocatechin-3-gallate (EGCG), a polyphenol abundant in green tea, can downregulate inducible NO synthase (iNOS) and TNF-α expression, and inhibit neuronal death via direct modulation of microglial activation both in SH-SY5Y and in primary rat mesencephalic cultures employed for studying PD (48). It also diminishes IL-6 and IL-1β in LPS-induced rats (48), and reduce the 6-OHDA-induced expression of TNF-α and IL-1β in SK-N-AS cells (49). EGCG also shows anti-inflammatory function toward MS patients and EAE mice (50,51).…”

Section: Protection Against Neuroinflammationmentioning

confidence: 99%

See 1 more Smart Citation

Natural products targeting cellular processes common in Parkinson's disease and multiple sclerosis

Han

Wang

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

The hallmarks of Parkinson's disease (PD) include the loss of dopaminergic neurons and formation of Lewy bodies, whereas multiple sclerosis (MS) is an autoimmune disorder with damaged myelin sheaths and axonal loss. Despite their distinct etiologies, mounting evidence in recent years suggests that neuroinflammation, oxidative stress, and infiltration of the blood-brain barrier (BBB) all play crucial roles in both diseases. It is also recognized that therapeutic advances against one neurodegenerative disorder are likely useful in targeting the other. As current drugs in clinical settings exhibit low efficacy and toxic side effects with long-term usages, the use of natural products (NPs) as treatment modalities has attracted growing attention. This mini-review summarizes the applications of natural compounds to targeting diverse cellular processes inherent in PD and MS, with the emphasis placed on their neuroprotective and immune-regulating potentials in cellular and animal models. By reviewing the many similarities between PD and MS and NPs according to their functions, it becomes evident that some NPs studied for one disease are likely repurposable for the other. A review from this perspective can provide insights into the search for and utilization of NPs in treating the similar cellular processes common in major neurodegenerative diseases.

show abstract

Section: Protection Against Neuroinflammationmentioning

confidence: 99%

“…EGCG can react with ROS and activate the Nrf2 signaling pathway (48). It inhibits MPP + -induced OS in PC12 cells via the SIRT1 pathway, and increases glutathione level and mitigates the OS-induced cell death in L-Dopa-treated PC12 cells (48).…”

Section: Protection Against Osmentioning

confidence: 99%

Natural products targeting cellular processes common in Parkinson's disease and multiple sclerosis

Han

Wang

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…In PD, EGCG is reported to improve motor impairments and offer neuroprotection by preventing neuroinflammation and neurodegeneration [ 106 ]. Despite the promising properties demonstrated in vitro and in vivo [ 107 ], only a single clinical trial exists using EGCG in PD management. Chan et al (2009) conducted a randomized, double-blind, placebo-controlled, phase II study to assess the neuroprotection effect of EGCG in de novo PD patients [ 93 ].…”

Section: Natural Compounds In Clinical Trials For Neurodegenerative D...mentioning

confidence: 99%

Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials

et al. 2023

View full text Add to dashboard Cite

Neurodegenerative diseases are caused by the gradual loss of neurons’ function. These neurological illnesses remain incurable, and current medicines only alleviate the symptoms. Given the social and economic burden caused by the rising frequency of neurodegenerative diseases, there is an urgent need for the development of appropriate therapeutics. Natural compounds are gaining popularity as alternatives to synthetic drugs due to their neuroprotective properties and higher biocompatibility. While natural compounds’ therapeutic effects for neurodegenerative disease treatment have been investigated in numerous in vitro and in vivo studies, only few have moved to clinical trials. This article provides the first systematic review of the clinical trials evaluating natural compounds’ safety and efficacy for the treatment of the five most prevalent neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and Huntington’s disease.

show abstract

“…In this study, long-term treatment with green tea extract resulted in positive effects on motor and behavioral performance of treated animals with respect to control, and in a reversal of DA levels in the striatum and protection against oxidative stress (Pinto et al, 2015 ). More details on the neuroprotective mechanisms of EGCG can be found elsewhere (Wang et al, 2022 ). Considering the accumulated pre-clinical evidence, the disease-modifying properties of EGCG should be further analyzed in clinical trials.…”

Section: Small Molecules From Natural Sources For Pd and Hd Drug Disc...mentioning

confidence: 99%

Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics

et al. 2023

View full text Add to dashboard Cite

Neurological motor disorders (NMDs) such as Parkinson's disease and Huntington's disease are characterized by the accumulation and aggregation of misfolded proteins that trigger cell death of specific neuronal populations in the central nervous system. Differential neuronal loss initiates the impaired motor control and cognitive function in the affected patients. Although major advances have been carried out to understand the molecular basis of these diseases, to date there are no treatments that can prevent, cure, or significantly delay the progression of the disease. In this context, strategies such as gene editing, cellular therapy, among others, have gained attention as they effectively reduce the load of toxic protein aggregates in different models of neurodegeneration. Nevertheless, these strategies are expensive and difficult to deliver into the patients' nervous system. Thus, small molecules and natural products that reduce protein aggregation levels are highly sought after. Numerous drug discovery efforts have analyzed large libraries of synthetic compounds for the treatment of different NMDs, with a few candidates reaching clinical trials. Moreover, the recognition of new druggable targets for NMDs has allowed the discovery of new small molecules that have demonstrated their efficacy in pre-clinical studies. It is also important to recognize the contribution of natural products to the discovery of new candidates that can prevent or cure NMDs. Additionally, the repurposing of drugs for the treatment of NMDs has gained huge attention as they have already been through clinical trials confirming their safety in humans, which can accelerate the development of new treatment. In this review, we will focus on the new advances in the discovery of small molecules for the treatment of Parkinson's and Huntington's disease. We will begin by discussing the available pharmacological treatments to modulate the progression of neurodegeneration and to alleviate the motor symptoms in these diseases. Then, we will analyze those small molecules that have reached or are currently under clinical trials, including natural products and repurposed drugs.

show abstract

Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson’s disease

Cited by 23 publications

References 117 publications

Natural products targeting cellular processes common in Parkinson's disease and multiple sclerosis

Natural products targeting cellular processes common in Parkinson's disease and multiple sclerosis

Therapeutic Potential of Natural Compounds in Neurodegenerative Diseases: Insights from Clinical Trials

Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics

Contact Info

Product

Resources

About